Table 4 Ongoing phase 3 clinical trials of novel immune checkpoint inhibitors or co-stimulators
From: Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Trial identifier | Check-points | Estimated enrolment | Disease | Arms | Estimated study completion date |
|---|---|---|---|---|---|
NCT04082364 | LAG-3 PD-1 | 82 (Actual) | HER2+ GC/GEJC | A: Margetuximab + Retifanlimab B: Margetuximab + Retifanlimab + Chemotherapy C: Margetuximab + Tebotelimab + Chemotherapy D: Margetuximab + Chemotherapy E: Trastuzumab + Chemotherapy | December 2023 |
NCT05064059 | LAG-3 PD-1 | 432 | PD-1+ colorectal cancer | A: Favezelimab + Pembrolizumab B: Regorafenib/ TAS-102 | November 2024 |
NCT05352672 | LAG-3 PD-1 | 1590 | Melanoma | A: Fianlimab + Cemiplimab B: Pembrolizumab + Placebo C: Cemiplimab + Placebo | April 2031 |
NCT03358875 | TIGIT | 805 | NSCLC | A: BGB-A317 B: Docetaxel | July 2023 |
NCT04256421 | TIGIT PD-L1 | 490 (Actual) | SCLC | A: Tiragolumab + Atezolizumab + CE B: Placebo + Atezolizumab + CE | March 2024 |
NCT04294810 | TIGIT PD-L1 | 635 | NSCLC | A: Tiragolumab + Atezolizumab B: Placebo + Atezolizumab | February 2025 |
NCT04543617 | TIGIT PD-L1 | 750 | ESCC | A: Tiragolumab + Atezolizumab B: Tiragolumab/Placebo + Atezolizumab C: Tiragolumab/Placebo + Atezolizumab/Placebo | December 2025 |
NCT04736173 | TIGIT PD-1 | 625 | NSCLC | A: Platinum-based Chemotherapy B: Zimberelimab C: Zimberelimab + Domvanalimab | June 2026 |
NCT04746924 | TIGIT PD-1 | 660 | NSCLC | A: Tislelizumab + Ociperlimab B: Pembrolizumab + Placebo C: Tislelizumab + Placebo | May 2025 |
NCT04866017 | TIGIT PD-L1 | 900 | NSCLC | A: Ociperlimab + Tislelizumab + CCRT B: Tislelizumab + CCRT C: Durvalumab + CCRT | September 2025 |
NCT05568095 | TIGIT PD-1 | 970 | UGTA | A: Domvanalimab + Zimberelimab + FOLFOX/CAPOX B: Nivolumab + FOLFOX/CAPOX | January 2027 |
NCT04128696 | ICOS PD-1 | 315 | HNSCC | A: Feladilimab+ Pembrolizumab B: Placebo+ Pembrolizumab | April 2023 |
NCT04266301 | TIM-3 | 530 (Actual) | MDS CMML-2 | A: MBG453 + Azacitidine B: Placebo + Azacitidine | January 2027 |
